Sergio Duron, Enlaza Therapeutics CEO
Enlaza launches with $61M, aims to take covalency into protein drugs
Covalent small molecule drug development has seen a bit of a renaissance in recent years. But a new San Diego-based biotech …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
